12 blockbuster sprints for the first class of new Chinese medicines are listed!

On October 9th, Kangyuan Pharmaceutical submitted a clinical application for the new drug of Jiuwei Shufeng Pingchuan Granules, which is the 37th class 1 new drug declared for Chinese patent medicine this year

12 Class 1 new drugs are sprinted to the market, and the market structure of 100 billion yuan will be reshaped

According to data from Menet.

Among the seven major categories in the Chinese patent medicine market with sales exceeding 10 billion, the market share of skeletal and muscle system disease drugs, digestive system disease drugs and urinary system disease drugs has increased year by year, and the potential cannot be underestimated.

Table 1: Status of new Chinese patent medicines declared for marketing from 2020 to now

Source: CDE official website, Minet database

Note: Some indications are compiled through public information

Statistics show that from 2020 to now, a total of 12 Chinese patent medicines have been declared for marketing in Class 1 new drugs.

Drugs for respiratory diseases are still highly popular.

In addition, Tasly and Yiling Pharmaceuticals, which are in the leading echelon of traditional Chinese medicine, also have outstanding performance.

Table 2: Status of Class 1 New Drugs Approved for Clinical Trials from 2020

Source: CDE official website, Minet database

Note: Some indications are compiled through public information

Since 2020, a total of 39 Chinese patent medicines have been applied for clinical application of Class 1 new drugs.

Twenty-three Class 1 new drugs approved for clinical use of Chinese patent medicines are distributed in nine categories.

There are 5 and 4 Class 1 new drugs for digestive system diseases and 4 drugs for skeletal and muscular system diseases.

Medical insurance negotiations "escort", six new drugs will bravely break into the new catalog

Table 3: New Chinese patent medicines approved for marketing since 2019 (statistics based on the date of approval)

Source: Meinenet MED2.

There are 2 new Chinese patent medicines approved for marketing in 2019, and 4 approved for marketing in 2020.

Pediatric Jingxing Cough Granules are transformed from clinical prescriptions and are used to treat acute bronchitis in children with wind-cold and heat-dissipating syndrome; Shaoma Zhijing Granules are used for Tourette syndrome (Tic-Tourette’s syndrome) and chronic tic disorder.

Figure 1: Sales of some new drugs in 2020 (unit: ten thousand yuan)

Source: Mi Nei Net Database

Before the implementation of the medical insurance negotiation catalogue, Sangzhi total alkaloid tablets and Lianhuaqing cough tablets have made a good start in physical pharmacies in Chinese cities.

According to the 2021 National Medical Insurance Drug Catalog Adjustment Work Plan, this year's work is divided into five stages: preparation, declaration, expert review, negotiation, and announcement of results

Huashibaidu Granules, Xuanfeibaidu Granules, and Qingfei Paidu Granules are the results of the transformation of the anti-epidemic "three prescriptions"; Jinrong Granules are transformed from clinically famous prescriptions to treat breast hyperplasia; Guanhuangmu Granules are mainly used for women's menopausal synthesis Adjuvant treatment of symptoms; Lianyu Burn Ointment is used for the treatment of superficial and deep second-degree burns and scald wounds

The leading Chinese medicine industry is struggling to catch up, and the chemical medicine giant breaks the ground, and the turning point of the industry has come.

For a long time, China's proprietary Chinese medicine market has problems such as large and fragmented manufacturing companies, serious product homogeneity, and lack of core competitiveness.
The industry urgently needs adjustment and upgrade
.
Key monitoring catalogues, medical insurance catalogue adjustments, large-scale purchases.
.
.
The New Deals that have appeared in turn in recent years have all been regarded as heavy blows to the industry's rectification
.

Judging from the situation of new Chinese patent medicines approved and declared in recent years, leading Chinese patent medicine companies such as Tasly, Yiling Pharmaceutical, Kangyuan Pharmaceutical, etc.
have spared no effort in the development of new medicines, and have carried out product lines from the perspective of the company itself.
After the product enters the harvest period, it will continue to strengthen the company’s competitiveness in the market
.
According to data from the 2020 annual report, Tasly’s R&D investment reached 600 million yuan, accounting for 9.
40% of the company’s pharmaceutical industry revenue; Yiling Pharmaceutical’s R&D investment exceeded 700 million yuan, accounting for 8.
39% of the company’s operating revenue; Kangyuan Pharmaceutical R&D The investment is close to 400 million yuan, accounting for 13.
04% of the company's operating income.
.
.
Leading Chinese patent medicine companies can also compete with the chemical drug giants in R&D investment, and continued to increase their efforts will eventually usher in a bumper harvest
.

It is worth noting that some chemical drug giants are no longer stingy and spend a lot of money on the research and development of new Chinese patent medicines.
This is also due to the continuous air blows at the top of the country to encourage the development of Chinese medicine
.
For example, Renfu, the leading drug company for anesthesia and sedation, and the company’s first class 1 new Chinese patent medicine, Guangxiancao total flavonoids capsules, immediately aroused heated discussions in the industry.
Renfu has been working hard in the field of Chinese patent medicines.
Among them, ethnic medicines are more outstanding.
The new drug is expected to bring new breakthroughs for the company in the field of medication for urinary system diseases
.

Traditional Chinese medicine has a long history and has natural advantages at the public level.
It is easier to be accepted by patients.
At present, the development of the Chinese medicine industry is highly valued at the national level and has been included in the national development strategy.
It is expected that policy support will continue in the future.
The turning point has come, and domestic pharmaceutical companies should seize the opportunity to make arrangements as soon as possible
.
On the other hand, how to do a good job in the commercialization of new Chinese medicines is also worthy of attention.
Problems such as restrictions on Western medicine prescriptions for Chinese medicines and long-term observation and verification of the efficacy of Chinese medicines make it difficult for new medicines to be recognized by doctors in the short term
.
In the wave of medical reform in the midst of the vicissitudes of life, the government, manufacturers, and doctors need to work together to let new Chinese medicines win the right to speak in the market
.

Source: CDE official website, Minet database

The review data statistics are as of October 13, if there are any errors or omissions, please correct me
.